MCRB

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study

Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting